De Novo Binders

About Monod Bio

Monod Bio is a private, pre-revenue biotechnology company that emerged as a spin-out from the University of Washington's Institute for Protein Design (Baker Lab) in 2022. The company's core technology is an AI/ML platform for de novo protein design, which it applies to develop novel protein binders and biosensors, including its flagship LuxSit™ Pro luciferase. Its business model focuses on creating Research Use Only (RUO) tools and In Vitro Diagnostics (IVD) for central lab and point-of-care settings, positioning it at the intersection of AI-driven drug discovery tools and diagnostics.